Skip to Main Content

Paper Details

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies.
Oncologist
3
2023
BRCA, HER2, HER2-Negative Early Breast Cancer, HER2-negative early breast cancer, Olaparib, abemaciclib, breast cancer, capecitabine, early-stage, gBRCA1/2m, germline BRCA1/2, olaparib, patients
Author NameAffiliation
Ana C Garrido-CastroDana-Farber Cancer Institute
Ana C Garrido-CastroBroad Institute of MIT and Harvard
Ana C Garrido-CastroHarvard Medical School
Ana C Garrido-CastroDana-Farber Brigham Cancer Center
Anna WeissUniversity of Rochester
Giuseppe CuriglianoEuropean Institute of Oncology, IRCCS
Giuseppe CuriglianoUniversity of Milan
Nancy U LinDana-Farber Cancer Institute
Nancy U LinHarvard Medical School
Nancy U LinDana-Farber Brigham Cancer Center
Judy E GarberDana-Farber Cancer Institute
Judy E GarberDana-Farber Brigham Cancer Center
Judy E GarberHarvard Medical School
Judy E GarberDana-Farber Cancer Institute
Sara M TolaneyDana-Farber Cancer Institute
Sara M TolaneyDana-Farber Brigham Cancer Center
Sara M TolaneyHarvard Medical School
  • 1 - 17

Datasets

Release 1.2